aibioKVUE Kenvue Inc.
Kenvue (KVUE) news
Top story · Oct 13, 2026 · SEC filing 8-K
Kenvue signs a material agreement
Entry into a Material Definitive Agreement On October 9, 2026, Kenvue Inc.
Latest Kenvue news
We have not published a story on Kenvue yet. When there is news, it will appear here.
What Kenvue does
Kenvue is a consumer health company that sells self care, skin health and beauty, and essential health products, with $15.1 billion in net sales for fiscal 2025. Its brands include Tylenol, Listerine, Neutrogena, Aveeno, BAND-AID, Johnson's, Nicorette and Zyrtec, and its products are marketed in more than 165 countries. The Self Care segment covers cough, cold and allergy, pain care and other over-the-counter medicines. Skin Health and Beauty covers face and body care and hair products, including Aveeno, Neutrogena, Lubriderm and Rogaine. Essential Health covers oral care, baby care and women's health, including BAND-AID, Listerine and o.b. tampons. Kenvue became an independent company after the separation from Johnson & Johnson, and it began trading on the New York Stock Exchange in May 2023. On November 2, 2025, it agreed to combine with Kimberly-Clark. Its shareholders approved the merger on January 29, 2026, and the Hart-Scott-Rodino waiting period expired on February 4, 2026. Other foreign regulatory approvals remain pending.
| Product or program | What it is | Stage |
|---|---|---|
| Tylenol | Pain care brand in the Self Care segment | |
| Zyrtec | Cough, cold and allergy brand in the Self Care segment | |
| Neutrogena | Skin health and beauty brand | |
| Listerine | Oral care brand in the Essential Health segment | |
| BAND-AID Brand | Essential Health brand |
Kenvue annual financials
| Line | FY ended Dec 28, 2025 | FY ended Dec 29, 2024 |
|---|---|---|
| Revenue | $15.12 billion | $15.46 billion |
| Research and development | $382.0 million | $408.0 million |
| Net income (loss) | $1.47 billion | $1.03 billion |
| Cash from operations | $2.20 billion | $1.77 billion |
| Cash and equivalents | $1.06 billion | $1.07 billion |
Questions about Kenvue
What is the ticker symbol of Kenvue?
Kenvue Inc. trades under the ticker KVUE on NYSE.
Where is Kenvue listed?
Kenvue Inc. is listed on NYSE.
What is the SEC CIK of Kenvue?
The SEC Central Index Key (CIK) for Kenvue Inc. is 1944048. Its filings are on SEC EDGAR.
How many shares does Kenvue have outstanding?
1,920,773,467 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Kenvue listed under?
Our directory records Kenvue Inc. under United States.
What does Kenvue do?
Our directory classifies Kenvue Inc. as: Consumer health / OTC pharmaceuticals. This is a directory classification, not a description of the pipeline.
What is the ISIN of Kenvue?
The ISIN recorded for Kenvue Inc. is US49177J1025.
Does aibio.space cover Kenvue?
aibio.space lists Kenvue Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Kenvue incorporated?
SEC records list its state or country of incorporation as DE.
What does Kenvue develop?
Kenvue is a consumer health company that sells self care, skin health and beauty, and essential health products, with $15.1 billion in net sales for fiscal 2025. Its brands include Tylenol, Listerine, Neutrogena, Aveeno, BAND-AID, Johnson's, Nicorette and Zyrtec, and its products are marketed in more than 165 countries.
What is Tylenol from Kenvue?
Tylenol: Pain care brand in the Self Care segment
What is Zyrtec from Kenvue?
Zyrtec: Cough, cold and allergy brand in the Self Care segment
What was Kenvue's revenue last year?
$15.12 billion for the fiscal year ended Dec 28, 2025, as reported to the SEC.
Is Kenvue profitable?
Kenvue Inc. reported net income of $1.47 billion for the fiscal year ended Dec 28, 2025, and generated $2.20 billion of cash from operations, per its annual report to the SEC.
How much does Kenvue spend on research and development?
$382.0 million in the fiscal year ended Dec 28, 2025, per its annual report.
Investor discussion: Kenvue
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
SEC filings and registration
- SEC name
- Kenvue Inc.
- CIK
- 1944048
- Industry (SIC)
- Perfumes, Cosmetics & Other Toilet Preparations (2844)
- US tickers
- KVUE (NYSE)
- State or country of incorporation
- DE
- Fiscal year ends
- January 3
- Filer category
- Large accelerated filer
- Business address
- 1 KENVUE WAY, SUMMIT, NJ, 07901
- Phone
- 908-874-1200
- Shares outstanding
- 1,920,773,467 as of 2026-07-31 (10-Q filed 2026-08-06)
- Former names
- JNTL, Inc.
Recent filings
Listing details
- Company
- Kenvue Inc.
- Ticker
- KVUE
- Listing
- NYSE
- Country or territory
- United States
- Business scope
- Consumer health / OTC pharmaceuticals
- ISIN
- US49177J1025
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction